September 7th, 2016
Posted by Caroline Popper, M.D., M.P.H.
The global molecular diagnostics market continues to grow and change at a rapid pace. Danaher’s recent announcement that they are building their diagnostics portfolio by acquiring Cepheid is just the latest example. Several trends are driving this growth including changes in clinical practice, innovations in technology, and a changing regulatory environment aimed at promoting point-of-care diagnostics.